

This is a pre print version of the following article:

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) / Buzzetti, E.; Pinzani, M.; Tsochatzis, E. A.. - In: METABOLISM, CLINICAL AND EXPERIMENTAL. - ISSN 0026-0495. - 65:8(2016), pp. 1038-1048. [10.1016/j.metabol.2015.12.012]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

09/01/2026 11:48

## **The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)**

**Elena Buzzetti, Massimo Pinzani, Emmanuel A. Tsochatzis**

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free Hospital  
and UCL, London UK

**Corresponding author:** Emmanuel A. Tsochatzis, UCL Institute for Liver and Digestive Health,  
Royal Free Hospital and UCL.

Email: [e.tsochatzis@ucl.ac.uk](mailto:e.tsochatzis@ucl.ac.uk), phone: (0044)2077940500 ext 31142

**Word count:** 4999

**Conflicts of interest:** None

**Abstract:**

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. Despite its high prevalence, only a small minority of affected patients develops inflammation and subsequently fibrosis and chronic liver disease, while most of them only exhibit simple steatosis. In this context, the full understanding of the mechanisms underlying the development of NAFLD and non-alcoholic steatohepatitis (NASH) is of extreme importance; despite advances in this field, knowledge on the pathogenesis of NAFLD is still incomplete. The 'two-hit' hypothesis is now obsolete, as it is inadequate to explain the several molecular and metabolic changes that take place in NAFLD. The "multiple hit" hypothesis considers multiple insults acting together on genetically predisposed subjects to induce NAFLD and provides a more accurate explanation of NAFLD pathogenesis. Such hits include insulin resistance, hormones secreted from the adipose tissue, nutritional factors, gut microbiota and genetic and epigenetic factors. In this article, we review the factors that form this hypothesis.

**Keywords:** NASH, insulin resistance, lipotoxicity, gut microbiome, metabolic syndrome, PNPLA3

## 1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is defined as the accumulation of fat in the liver in patients who do not consume excessive alcohol. The prevalence of NAFLD is 20-30% in adults and is higher in industrialized countries [1]. NAFLD is asymptomatic in most affected patients and is associated with obesity and features of the metabolic syndrome, namely hypertension, dyslipidemia, central adiposity and insulin resistance (IR) or diabetes [2, 3]. **The term NAFLD encompasses a wide spectrum of conditions, from simple accumulation of fat ('fatty liver' or steatosis) to steatohepatitis (NASH), fibrosis and cirrhosis with its clinical consequences [4].**

Despite its high prevalence, only a small proportion of subjects with NAFLD has NASH with consequent higher risk of liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (Figure 1). While patients with simple fatty liver have similar life expectancy to the general population, those with NASH have an impaired survival, due primarily to cardiovascular and liver-related causes. This concept was recently challenged by two studies with longitudinal follow-up, which showed that advanced fibrosis, but not the presence of NASH (as diagnosed by the NAS score) predicted overall mortality in patients with NAFLD [5, 6]. The diagnosis of NAFLD remains one of exclusion and liver biopsy is still the gold standard to differentiate fatty liver from NASH and to stage fibrosis, although several noninvasive markers have been recently introduced for the latter [7].

The underlying mechanism for the development and progression of NAFLD is complex and multifactorial. Different theories have been formulated, leading initially to the 'two hits

hypothesis'. According to this, hepatic accumulation of lipids secondary to sedentary lifestyle, high fat diet, obesity and insulin resistance, acts as the first hit, sensitizing the liver to further insults acting as a 'second hit'. The 'second hit' activates inflammatory cascades and fibrogenesis [8]. This has been supported by animal models of obesity, such as the leptin deficient ob/ob mice, characterized by increased hepatic lipid accumulation, where a second insult is necessary to initiate inflammation and fibrosis [9].

However, it became rapidly evident that this view is too simplistic to recapitulate the complexity of the human NAFLD where multiple parallel factors, acting synergistically in genetically predisposed individuals, are implicated in the development and progression of disease.

Consequently, a multiple-hit hypothesis has now substituted the outdated two-hit hypothesis for the progression of NAFLD. In this review, we explore the potential mechanisms that are implicated in the pathogenesis and progression of NAFLD and that delineate the multiple-hit hypothesis.

### **1.1 Multiple hit hypothesis – an overview**

Dietary habits, environmental and genetic factors can lead to the development of insulin resistance, obesity with adipocyte proliferation and changes in the intestinal microbiome.

Insulin resistance is one of the key factors in the development of steatosis/NASH and results in increased hepatic de novo lipogenesis (DNL) and impaired inhibition of adipose tissue lipolysis, with consequent increased flux of fatty acids to the liver [10]. Insulin resistance also promotes

adipose tissue dysfunction with consequent altered production and secretion of adipokines and inflammatory cytokines [11].

Fat accumulates in the liver in the form of triglycerides, and this happens contemporarily with increased lipotoxicity from high levels of free fatty acids, free cholesterol and other lipid metabolites: as a consequence, mitochondrial dysfunction with oxidative stress and production of reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress associated mechanisms, are activated [12].

Also, altered gut flora leads to further production of fatty acids in the bowel, increased small bowel permeability and thus increased fatty acid absorption and raised circulating levels of molecules which contribute to the activation of inflammatory pathways and release of proinflammatory cytokines such as IL-6 and TNF-  $\alpha$  [13].

In subjects predisposed by genetic factors or epigenetic modifications, all these factors affect hepatocyte fat content and liver inflammatory environment, thus leading to a state of chronic hepatic inflammation (Figure 2) through heterogeneous hepatocellular damage pathways, with possible progression to hepatocellular death (for both direct toxicity and apoptosis activating mechanisms), activation of hepatic stellate cells and deposition of fibrous matrix.

Although the dictum was that steatosis always precedes inflammation, it is now recognized that NASH can be the initial liver lesion: the timing and combination of genetic, external and intracellular events rather than the simple sum of hepatic insults result in different pathways which lead to steatosis or NASH respectively [14].

This could be due to shortcomings of the NAS score, as the presence and grading of steatosis has a disproportionate impact compared to lobular inflammation and ballooning, while portal inflammation is not part of the score [15]. Alternatively, lobular inflammation and ballooning could be epiphenomena similarly to simple steatosis, not related to the activation of fibrogenic pathways.

**Commented [MT1]:** Move to the introduction immediately after references 5 and 6.

## 2. Fat metabolism, lipotoxicity and insulin resistance

Fat accumulates in the liver of patients with NAFLD mainly in the form of triglycerides [16, 17]. Triglycerides derive from esterification of glycerol and free fatty acids (FFA). Once synthesized, triglycerides enter storage or secretory pools, which have distinct rates of turnover. FFAs derive either from diet or from the adipose tissue via lipolysis and/or from hepatic DNL. Once in the hepatocytes, FFA undergo acyl-CoA synthetase activity and form fatty acyl-CoAs, which may enter either esterification or  $\beta$ -oxidation pathways [18].

Triglyceride accumulation is not hepatotoxic per se and could represent a defensive mechanism to balance FFAs excess as demonstrated in mice models [19, 20]. The inhibition of triglyceride incorporation into new VLDL by blocking MTP causes impaired triglyceride secretion and therefore triglyceride accumulation without liver injury [21]; inhibition of DGAT2 expression, a key enzyme involved in triglyceride formation, resulted in a reduction of intrahepatic triglycerides and subsequent increased FFA oxidation and worsening of steatohepatitis in mice models [20]. Therefore increased triglyceride concentration is an epiphenomenon which happens simultaneously with toxic metabolites generation, lipotoxicity and liver injury [22].

Hepatic DNL can be increased by activation of transcription factors such as sterol regulatory element-binding protein-1 (SREBP-1), carbohydrate response element-binding protein (ChREBP) and peroxisome proliferator-activated receptor (PPAR)- $\gamma$  [23]. SREBP-1 is a transcriptional factor present as three isoforms: while SREBP-1c regulates the activation of DNL and is stimulated by insulin [24], SREBP-2 is involved in cellular cholesterol homeostasis, therefore their dysregulation is involved in hepatic fat accumulation [17]. ChREBP is activated by glucose and increases DNL but also provides more substrate for triglyceride and FFA synthesis. Irrespective of the underlying mechanism, patients with NAFLD have increased DNL compared to controls, which is not suppressed on fasting, and higher nocturnal plasma levels of FFAs [25].

Among the insulin receptors, insulin receptors substrate 2 (IRS-2) can work, when activated, as a regulator of SREBP-1c, influencing DNL [26]. In states of insulin resistance IRS-2 is down-regulated, therefore SREBP-1c is over-expressed and DNL is up-regulated [27]. Also,  $\beta$ -oxidation of FFAs is inhibited in insulin resistance states, thus further promoting hepatic lipids accumulation [28].

FFAs in hepatocytes may induce defects in insulin signaling pathways through serine-kinase activation and contribute to insulin resistance state [29] [30]. Furthermore, insulin has a potent action to suppress adipose tissue lipolysis: in insulin resistance states, this suppression is impaired, resulting in increased efflux of FFAs to the liver [31]. Other pathways of fat disposal such as impaired hepatic fatty acid oxidation or reduced synthesis or secretion of VLDL have less importance in determining fat accumulation and lipotoxicity in NAFLD [32]. Autophagy,



which regulates lipid metabolism, decreases in liver steatosis, thus resulting in a vicious cycle of lipid accumulation and further suppression of the autophagic function [33].

Insulin resistance is a cardinal feature of NAFLD and is more prevalent in NASH compared to simple steatosis [34]. Patients with hepatic steatosis and NASH but without type 2 diabetes have decreased insulin sensitivity [35, 36]. Insulin resistance is one of the 'multiple hits' predisposing to the development of NAFLD and progression to NASH, critical for the establishment of lipotoxicity, oxidative stress and inflammatory cascade activation [8]. In patients with NAFLD, both genetic and environmental factors further interfere with the insulin signaling cascade and therefore contribute to the maintenance and worsening of insulin resistance: serine phosphorylation of insulin receptor substrate by inflammatory signal transducers such as c-jun N-terminal protein kinase 1 or inhibitor of nuclear factor- $\kappa$ B kinase- $\beta$  (IKK $\beta$ ) [37], activation of nuclear factor kappa B (NF- $\kappa$ B) and SOCS (suppressors of cytokine signaling) [38] are some of the mechanisms that may disrupt insulin signaling in patients with NAFLD.

### 2.1. Mitochondrial dysfunction

Structural and functional alterations in mitochondria contribute to the pathogenesis of NAFLD. Structural alterations encompass depletion of mitochondrial DNA, morphological and ultrastructural changes, while functional alterations include the respiratory chain and mitochondrial  $\beta$ -oxidation [39].

If mitochondrial or peroxisomal function cannot handle the increased lipid flux, respiratory oxidation may collapse with impairment of fat homeostasis, generation of lipid-derived toxic

metabolites and overproduction of ROS [40]. All these molecules activate inflammatory pathways contributing to hepatocytes necroinflammation [12] and worsening of mitochondrial damage.

It has been indeed demonstrated that there is a correlation between insulin resistance, obesity, TNF- $\alpha$  levels and mitochondrial dysfunction [41]. Furthermore ROS, together with oxidized LDL particles, may activate Kupffer and hepatic stellate cells, leading to inflammation and fibrosis [42].

Whether mitochondrial dysfunction is a key pathogenic event in NAFLD or the consequence of an altered lipid metabolism still remains unclear.

## 2.2. Endoplasmic reticulum stress

An increased protein synthetic input, a primary dysfunction of the ER or lack of ATP can lead to unfolded proteins accumulation within the ER, activating the so called 'unfolded protein response' (UPR), which is an adaptive response aiming to resolve ER stress. UPR activation involves adaptive mechanisms such as reduction of protein synthesis, increased capacity for protein transit through the ER, increased protein folding and transport and activation of pathways for protein degradation, which help in resolving the protein-folding defect which would otherwise lead to initiation of apoptosis [43].

In NAFLD, factors that induce UPR include hyperglycemia, mitochondrial injury that depletes ATP, hypercholesterolemia, depletion of phosphatidylcholine and oxidative stress [44].

UPR leads to the activation of c-jun terminal kinase (JNK), an activator of inflammation and apoptosis: its silencing in animal models leads to decreased steatosis and steatohepatitis [45], while its activity has been showed as one of the features which differentiate subjects with NASH from those with simple steatosis [46]. Furthermore, JNK activity is linked to impairment of insulin signaling and subsequent development of diabetes mellitus [47].

Another consequence of UPR is the activation of SREBP-1c pathways and therefore maintenance of liver fat accumulation and further aggravation of ER stress and of UPR [48].

X-Box binding protein-1 (XBP-1) is one of the main regulators of UPR and interacts with the PI3K insulin signaling pathway, with increased nuclear translocation induced by insulin [49]. The interaction of PI3K and XBP-1 is both modulated by and modulates the cellular response to ER stress [50]. XBP-1 has been therefore proposed as the missing link between steatosis, insulin resistance and inflammation [51].

### 2.3. Inflammatory state in NAFLD: IL-6 and TNF- $\alpha$

Increased levels of FFAs and consequent lipotoxicity, insulin resistance, peripheral adipose tissue dysfunction and gut derived endotoxins concur in activating and maintaining the production and release of pro-inflammatory cytokines, both systemically and locally in the liver.

Two main inflammatory pathways, JNK-AP-1 and IKK-NF- $\kappa$ B, are critically involved in the development of the chronic inflammatory state in NAFLD [52]. As previously mentioned, JNK is a member of mitogen activated protein kinases, associated with activation of apoptosis and development of NASH.

Nuclear factor- $\kappa$ B kinase- $\beta$  (NF- $\kappa$ B) is a transcription factor and a primary regulator of inflammatory activation, and its IKK2 subunit is the major component required for its activation during the acute inflammatory response [53]. Persistent NF- $\kappa$ B pathway activation has been shown in animal models of NAFLD [54] as well as in patients with NASH [55]. IKK2 overexpression and persistent activation of NF- $\kappa$ B in hepatocytes lead to a chronic inflammatory state and insulin resistance [54].

The key role of the hepatic production of cytokines in the progression from steatosis to NASH is supported by studies in animal models demonstrating that hepatic exposure to increased levels of proinflammatory cytokines leads to histological changes typically seen in NASH, such as hepatocyte necrosis and apoptosis, neutrophil chemotaxis, activation of hepatic stellate cells and production of Mallory bodies [56]. Furthermore, serum and hepatic levels of TNF- $\alpha$  are increased in patients with NASH and correlate with histological severity of liver damage [57].

In addition, inflammation and NF- $\kappa$ B activation can promote carcinogenesis, and therefore the chronic inflammatory state of NAFLD may play a role in HCC development [58].

#### 2.4. Inflammasome activation

Inflammasomes are cytoplasmic multi-protein complexes, consisting of caspases and molecules derived from pathogen microorganisms or liberated by injured cells, which can trigger inflammation. They act as sensors of endogenous or exogenous pathogen-associated molecular pattern molecules (PAMPs) or damage-associated molecular patterns (DAMPs). As part of the innate immune system activity, inflammasomes contribute to immune activation in response to different stimuli [59]. They regulate effector pro-inflammatory cytokines by activation of

families of germ-line encoded pattern recognition receptors (PRRs) as the Toll-like receptors (TLRs), NOD-like receptors (NLRs) and C-type lectin receptors (CLRs). Release of DAMPs can be induced by several mechanisms such as cell necrosis, apoptotic cells that are not removed by phagocytes and oxidative stress [8].

The activation of inflammasomes in response to FFAs, oxidative stress and other pro-inflammatory metabolites seen in NAFLD with consequent production of IL-1 $\beta$  could have an important role in the development of NASH, by inducing suppression of peroxisome proliferator-activated receptor- $\alpha$  (PPAR- $\alpha$ ), and promoting the indirect effect of TNF- $\alpha$ -induced cell death [60]. Inflammasomes could also have a direct effect on hepatic stellate cells and promote fibrosis [61]. In NASH, saturated fatty acids up-regulate the inflammasome, trigger the release of danger signals from hepatocytes in a caspase-dependent manner and induce sensitization to LPS for IL-1 $\beta$  release in hepatocytes [62]. Conversely, mice with NLRP3 inflammasome loss of function are protected from diet-induced NASH [63].

Kupffer cells are important for inflammasome activity [64]: they express high levels of IL-1 $\beta$  mRNA and their reduction results in decreased total liver IL-1 $\beta$  mRNA and also decreased serum levels of IL-1 $\beta$  [65]. In murine models of NASH, signaling through TLR9 activation stimulates Kupffer cells to produce IL-1 $\beta$  with consequent steatosis, inflammation and fibrosis [60, 65]. Modulation of the Kupffer cells phenotype may represent a possible therapeutic antifibrotic strategy [66].

Accordingly, expression of inflammasome-associated proteins (NLRP3, pro-IL-1 $\beta$ , and pro-IL-18) is significantly higher in patients with NASH compared to those with simple steatosis [63].

### **3. Adipose tissue dysfunction**

Adipose tissue is not inert as traditionally thought but has an endocrine function and secretes hormones (adipokines) such as leptin and adiponectin [67].

**Obesity-related adipocyte hypertrophy and/or insulin resistance result in an imbalance of adipokines that may profoundly affect not only the adipose tissue itself but also the liver** [68].

Adipose tissue contributes to the maintenance of low-grade inflammatory states by producing pro-inflammatory cytokines: serum levels of IL-6 and adipocytes expression of TNF- $\alpha$  are increased in obese patients and subsequently decline following weight loss [69, 70]. Furthermore, increased expression of inflammatory genes and macrophages activation in the visceral and subcutaneous adipose tissue of patients with NAFLD correlates with progression from simple steatosis to NASH and fibrosis [71].

Leptin is a 16-kiloDalton anorexigenic hormone with pro-inflammatory actions that prevents lipid accumulation in non-adipose sites; in the liver this is achieved by lowering the expression of SREBP-1 [72]. However, leptin increases in obese subjects as a consequence of leptin resistance and its pro-fibrogenic role has been demonstrated in various in vitro and animal models [73, 74]. Leptin activates hepatic stellate cells through the hedgehog [75] and mTOR [76] pathways. It was suggested that Kupffer cells are targeted by leptin and are stimulated to produce TGF- $\beta$ 1 and subsequently activate hepatic stellate cells [77]. Low-dose gut-derived endotoxin induces hyper-responsiveness to leptin-mediated signaling and subsequent upregulation of CD14 and accelerated fibrosis in NASH mice [78]. In mice models of NASH cirrhosis, hyperleptinaemia aggravates intrahepatic resistance and portal hypertension [79].

Despite the abundance of data in animal models, the effects and significance of serum leptin levels in patients with NAFLD or NASH is still unspecified. [80].

**Adiponectin improves hepatic and peripheral insulin resistance and has anti-inflammatory and hepato-protective activities [81]. These effects are partly achieved by enhancing the deacylation of the sphingolipid ceramide independently of AMPK, especially in hepatocytes, cardiomyocytes and  $\beta$ -cells [82].** The anti-inflammatory effects are achieved through blocking the activation of NF- $\kappa$ B, secreting anti-inflammatory cytokines and inhibition inhibiting the release of pro-inflammatory cytokines such as TNF- $\alpha$  and IL-6 [83]. Adiponectin also has a direct antifibrotic effect [84], which could be mediated by the activation of AMPK [85]. Enhanced liver fibrosis has been demonstrated in mice lacking adiponectin [84], while delivery of recombinant adiponectin significantly improved steatohepatitis in mice [86]. The antioxidant effects of adiponectin are mediated through its receptor AdipoR1, therefore their decreased levels in obesity may have causal roles in mitochondrial dysfunction and insulin resistance [87]. In obese patients, reduced adiponectin and increased leptin levels may result in hepatic steatosis and activation of inflammation and fibrogenesis [80].

#### **4. Genetic determinants**

Genetic variants, especially in the form of single nucleotide polymorphisms, influence hepatic FFAs flux, oxidative stress, response to endotoxins and cytokine production and activity, and are determinants of NAFLD development and progression [88].

Genome-wide association studies have established the role of patatin-like phospholipase 3 (PNPLA3) single nucleotide polymorphisms in the development and progression of NAFLD, in

particular the I148 M (rs738409 C/G) variant. PNPLA3 gene encodes for a protein called adiponutrin which has significant homologies to enzymes implicated in lipid metabolism processes and could exert a lipolytic activity on triglycerides [89].

The PNPLA3 148M allele is associated with lower DNL and expression of the lipogenic transcription factor SREBP1c, despite a substantially increased hepatic fat content, while hepatic  $\beta$ -oxidation is apparently not influenced by the PNPLA3 genetic variant [90]. Furthermore, hepatic lipid accumulation in PNPLA3 148M carriers is associated with decreased secretion of triglyceride-rich lipoproteins from the liver [91].

PNPLA3 I148M knock-in mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis [92]. In humans, this polymorphism is associated with increased steatosis and fibrosis and is responsible for 5.3% of the total genetic variance attributed to NAFLD [93]. This variant has similar effect size in European and African- and Hispanic-American ancestries, with a variation of frequency in the effect G allele [94].

The above observation was confirmed in a recent meta analysis of 23 studies, where a significant association between the rs738409 PNPLA3 polymorphism and the risk of NAFLD (OR=3.41) and NASH (OR=4.44) was demonstrated [95]. In a case control study of 100 patients with NAFLD-related HCC and 275 NAFLD controls, the G allele conferred an additive risk for HCC (adjusted OR 2.26) [96].

A variant of transmembrane 6 superfamily member 2 (TM6SF2) gene is also possibly involved in NAFLD pathogenesis [24]. TM6SF2 protein promotes VLDL secretion, while the rs58542926 variant, through a loss of function, is associated with hepatic steatosis, lower plasma levels of



VLDL and higher ALT levels [97]. The TM6SF2 minor allele was associated with advanced hepatic fibrosis in two cohorts of NAFLD, comprising 349 and 725 patients (derivation and validation cohort) respectively [98]. Despite of being at higher risk of NASH progression, carriers of this variant are protected against cardiovascular disease, probably due to reduced VLDL levels [99].

#### 5. **Epigenetic factors**

Clinical studies investigating epigenetic reprogramming in NASH are just beginning to emerge.

Epigenetic modifications are stable changes at transcriptional level, such as DNA methylation, histones modifications and activity of microRNAs (miRNAs), which do not alter the basic DNA sequences and contribute to the cell homeostasis exhibiting a high degree of developmental and environmentally driven plasticity [100]. It has been hypothesized that the disruption of this balance may determine an increased susceptibility for NAFLD [101]. In a study on mice models of diet-induced NASH, an association between epigenetic modifications, particularly pronounced loss of genomic and repetitive sequences cytosine methylation, and the development NASH was observed [102].

DNA methylation is considered as one of the important determinants in the process leading from simple steatosis to NASH and is mostly influenced by dietary deficiency of fundamental methyl donors such as betaine, choline and folate [103]. Supplementation of betaine is associated with a reduced methylation of the MTP promoter and consequent promotion of triglyceride export from the liver [104]. Folate influences the expression of genes involved in FFA synthesis and its deficiency induce triglyceride accumulation in the liver [105] while feeding mice with a methionine and choline deficient diet results in one of the most common murine

models of NASH, probably caused by the depletion of mitochondrial S-adenosyl-L-methionine and glutathione [106].

Alteration of histone acetylation, mediated by histone deacetylases (HDACs) and histone acetyltransferases (HATs), is another frequent modification and also one of the most studied. Sirtuins (SIRT, silent information regulator-2 family) form a group of proteins with deacetylase activity; SIRT1 in particular regulates proteins involved in metabolic processes such as glucose homeostasis, oxidative stress, lipid metabolism and inflammatory activity. It also modulates genes such as FXR and LXR and is regulated by JNC [101]. A correlation between reduced expression of SIRT1 or its decreased activity and NAFLD has been demonstrated in both animal models and humans [107, 108].

Epigenetic modifications can be inherited from parents to their offsprings: rats born from mothers fed with high fat diet showed a NAFLD phenotype, as well as DNA hypo-methylation of an hepatic cell cycle inhibitor (Cdkn1) whose subsequent overexpression has been associated to hepatocyte growth in pathological states [109]. Furthermore, high-fat maternal diet in mice correlated with reduced HDAC1 proteins in the fetal liver [61], possibly leading to changes in fetal chromatin [110].

In a study that included morbidly obese patients with all stages of NAFLD and healthy controls, NAFLD-specific expression and methylation differences were seen for nine genes coding for key enzymes in intermediate metabolism and insulin/insulin-like signaling. These NAFLD-specific methylation changes were partially reversible after bariatric surgery. [111].

It has furthermore been demonstrated that non-coding RNAs regulate epigenetic mechanisms of gene expression. Studies on non-coding RNAs in NASH have so far been limited to miRNAs. MiRNAs are small endogenous single-stranded RNA molecules which, by influencing transcriptional and post-transcriptional regulation of gene expression, regulate different cellular processes like proliferation, apoptosis, differentiation and cellular growth [112]. Variations in the expression and circulating levels of miRNAs have been linked to the pathogenesis of NAFLD/NASH: several miRNAs are differentially expressed in subjects with NASH and are associated with glucose and lipid metabolism [113] [114]. MiR-122 is the most abundant miRNA in the liver; studies on animal models have demonstrated that its inhibition leads to reduced plasma cholesterol levels and altered expression of hepatic genes involved in cholesterol and fatty acids synthesis [115]. A human study demonstrated that 113 miRNAs were differentially expressed in the visceral adipose tissue of subjects with NASH as compared to those with simple steatosis: of these, seven were significantly associated to the presence of NASH and were involved in regulation of genes of insulin-related, inflammatory and metabolic pathways, while two (miR-197, miR-99) also correlated with the presence and extent of liver fibrosis [116].

## **6. Dietary factors**

Dietary factors, both in terms of quantity and caloric intake but also of specific nutrients, contribute to the development of NAFLD and NASH. In a study of 18 healthy individuals, doubling the regular caloric intake with fast-food based meals resulted in profound ALT elevations and increased steatosis in less than 4 weeks [117].

Fructose is a lipogenic, pro-inflammatory dietary factor that results in oxidative stress and upregulation of TNF- $\alpha$  [118]. **It is cleared by the liver within first-pass metabolism by 90% and is metabolized by specific hepatic kinases, independently of insulin action, into fructose-1-phosphate. This metabolite is converted into triose phosphate, which enters the glycolytic pathway generating substrates for DNL** [119]. In mice models, fructose-induced NAFLD is associated with bacterial overgrowth and increased intestinal permeability [120]. Fructose can also induce copper deficiency in mice and subsequent NAFLD [121]. In patients with NAFLD, daily fructose ingestion is associated with increased fibrosis [122] and it has been suggested that this is due to industrial rather than fruit-derived fructose [123]. This effect could be mediated by the depletion of hepatic ATP [124].

**Sweetened beverages that contain fructose-containing sugars such as sucrose and high fructose corn syrup are associated with increased risk of developing steatosis and NASH, especially in overweight/obese individuals** [125].

Conversely, coffee is protective in patients with NAFLD [126]; this action is due to various antioxidants but also to the caffeine per se [127, 128] .

Mono-unsaturated fats, which are typical in a Mediterranean type diet, are protective of NAFLD. In a small 6-week randomized trial, the Mediterranean diet improved steatosis and insulin resistance even without weight loss in patients with insulin resistance and NAFLD [129].

**Regarding alcohol, it has been suggested that moderate alcohol consumption is protective in NAFLD. In ob-ob mice, moderate amounts of alcohol, resulted in less steatosis, inflammation and lower transaminases compared to controls: this effect was achieved by activation of**

sirtuin1/adiponectin-signaling pathway in the visceral fat tissue and Akt, a key insulin signaling mediator [130]. Conversely, in wild type mice combination of high fat diet and intermittent alcohol consumption was associated with increased steatosis, inflammation and fibrosis [131].

In humans, light to moderate alcohol consumption was associated with reduced incidence of NAFLD in a Japanese study of over 5000 individuals [132]. In a meta-analysis of more than 40,000 individuals, moderate alcohol consumption was associated with reduced prevalence of NAFLD in the general population and of NASH in patients with NAFLD [133]. The above finding will need validation in prospective cohorts.

#### **Influence of the microbiota: the gut-liver axis**

It is increasingly recognized that the gut microbiome is implicated in the pathogenesis and progression of NAFLD, through the so-called gut-liver axis. A detailed analysis of the human microbiome has been performed and distinct “enterotypes” are recognized [134]. An obese microbiome has been demonstrated in mice models, which has an increased capacity to harvest energy from the diet [135]. Moreover, this obesity trait is transmissible, as colonization of germ-free mice with the 'obese microbiome' results in a significantly greater increase in total body fat than colonization with a 'lean microbiome' [135].

By receiving more than 50% of its blood supply from the splanchnic district, the liver is one of the most exposed organs to gut-derived toxins and also represents the first line of defense against bacterial-derived products. The cross-talk between host and microbiota at the intestinal mucosal interface is fundamental for the development and homeostasis of the host innate and

adaptive immune system [136]. Lipopolysaccharide (LPS) is one of the main toxic bacterial products and it may act, linked to co-receptor CD14, as ligand for TLR with consequent activation of the inflammatory cascade, including stress-activated protein kinases, JNK, p38, interferon regulatory factor 3 and nuclear factor- $\kappa$ B, pathways which have demonstrated effects on insulin resistance, obesity, hepatic fat accumulation and NASH development and progression [136, 137]. Certain patterns of microbiome diversities can enhance intestinal mucosal permeability and result in lipopolysaccharidemia. Patients with NAFLD have significantly increased gut permeability and a higher prevalence of small intestine bacterial overgrowth compared to healthy controls. [138]. The significant correlation between intestine bacterial overgrowth and NASH is observed even in the absence of increased mucosal permeability [139].

The gut microbiota impact on the host energetic balance by fermenting resistant starch and non-starch polysaccharides to short-chain fatty acids (SCFA), mainly acetate, propionate, and butyrate, and by making them absorbable by the intestinal epithelium [140]. Furthermore, enteric bacteria suppress the synthesis of fasting-induced adipocyte factor (Fiaf) resulting in increased lipoprotein lipase activity and increased triglyceride accumulation [51]. Gut microbiota also produces enzymes that catalyse the conversion of dietary choline into toxic compounds (particularly methylamines). These amines can be uptaken by the liver, transformed to trimethylamine-Noxide and induce inflammation and liver injury [141]. As shown in a recent study, microbiota dysbiosis can promote NASH by either reducing choline levels or increasing methylamines levels [142]. Another mechanism through which gut microbiota promotes NAFLD is the alteration of bile acid metabolism influencing farnesoid X receptor (FXR) signaling and therefore processes such as hepatic DNL and VLDL export [143].

Intestinal microbiota is also the major source of endogenous alcohol production and obesity-associated abnormalities of intestinal microbiome correlate with elevated breath alcohol levels in murine models [144]: in a similar way, a study aiming at identifying possible differences in gut microbiomes of NASH, obese, and healthy children, showed an abundance of alcohol-producing bacteria in NASH microbiomes with a subsequent increase in blood-ethanol concentrations [145]. This hypothesis could explain the similarity of hepatic histological and genetic features that exist between alcoholic and nonalcoholic liver disease.

Finally, defects in the NALP3 inflammasome are associated with lower levels of IL-18 and other cytokines in the intestine, resulting in modulation of the gut microbiome. This is associated with increased influx of TLR4 and TLR9 agonists into the portal circulation and subsequently more severe NASH. Remarkably, co-housing of wild-type mice with mice defective in inflammasome, led to the transmission of a NASH phenotype through the transmission of the altered microbiome [146].

## **7. Conclusions**

The pathogenesis of NAFLD and its progression is a complex process, which cannot be completely explained by the 'two-hit' hypotheses. It is becoming increasingly evident that the different histological patterns of NAFLD, namely simple steatosis and NASH not only have different risk of progression but may also reflect different disease entities in terms of pathogenesis. A number of diverse parallel processes contribute to the development of steatosis and liver inflammation. The gut microbiome has a key role through the gut-liver axis, together with insulin resistance, hormones secreted from the adipose tissue and obesity.

Changes in the gut microbiota as seen in obesity and insulin resistance have consequences both on energy homeostasis and systemic inflammation secondary to endotoxemia. At the liver level, FFAs overflow may result in ER stress and activation of the UPR or mitochondrial dysfunction and consequent activation of inflammatory responses. Furthermore, genetic factors might explain certain more progressive disease courses in NAFLD.

Further characterization of such pathways is important for the development of new non-invasive markers of NASH and fibrosis and for targeted pharmacological treatments.



Acknowledgments: Dr Buzzetti was supported by an educational grant from AIGO (Associazione Italiana Gastroenterologi Ospedalieri) and MIMI (Montecatini Interactive Medicine International).

## **References**

- [1] Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med*. 2002;346:1221-31.
- [2] Hassan K, Bhalla V, El Regal ME, HH AK. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. *World J Gastroenterol*. 2014;20:12082-101.
- [3] Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2008;27:80-9.
- [4] Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol*. 2010;53:372-84.
- [5] Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015;149:389-97 e10.
- [6] Ekstedt M, Franzen LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. *Scand J Gastroenterol*. 2012;47:108-15.
- [7] Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. *Int J Endocrinol*. 2015;2015:343828.
- [8] Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. *Int J Mol Sci*. 2014;15:8591-638.
- [9] Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. *Prog Lipid Res*. 2013;52:165-74.

- [10] Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. *Curr Pharm Des.* 2010;16:1941-51.
- [11] Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat Rev Mol Cell Biol.* 2008;9:367-77.
- [12] Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. *Clin Liver Dis.* 2009;13:545-63.
- [13] Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. *Clin Biochem.* 2015.
- [14] Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? *Aliment Pharmacol Ther.* 2012;36:815-23.
- [15] Brunt EM. Histopathology of non-alcoholic fatty liver disease. *Clin Liver Dis.* 2009;13:533-44.
- [16] Jacome-Sosa MM, Parks EJ. Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. *Curr Opin Lipidol.* 2014;25:213-20.
- [17] Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. *Prog Lipid Res.* 2013;52:175-91.
- [18] Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. *World J Gastroenterol.* 2014;20:1746-55.
- [19] Koliwad SK, Streeper RS, Monetti M, Cornelissen I, Chan L, Terayama K, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. *J Clin Invest.* 2010;120:756-67.

- [20] Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology*. 2007;45:1366-74.
- [21] Liao W, Hui TY, Young SG, Davis RA. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. *J Lipid Res*. 2003;44:978-85.
- [22] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. *Hepatology*. 2010;52:774-88.
- [23] George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. *Mol Pharm*. 2008;5:49-59.
- [24] Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. *Genes Dev*. 2000;14:2831-8.
- [25] Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology*. 2014;146:726-35.
- [26] Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. *World J Gastroenterol*. 2008;14:2474-86.
- [27] Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of Fatty liver. *Endocr Rev*. 2008;29:939-60.

- [28] Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J Clin Invest*. 2008;118:829-38.
- [29] Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. *Diabetes*. 2005;54 Suppl 2:S73-8.
- [30] Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest*. 2006;116:1793-801.
- [31] Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr Rev*. 2002;23:201-29.
- [32] Bertolani C, Marra F. The role of adipokines in liver fibrosis. *Pathophysiology*. 2008;15:91-101.
- [33] Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. *Nature*. 2009;458:1131-5.
- [34] Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology*. 2002;35:367-72.
- [35] Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology*. 2001;120:1183-92.
- [36] Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? *Clin Nutr*. 1999;18:353-8.
- [37] Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science*. 2008;322:1539-43.

- [38] Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. *Nat Rev Mol Cell Biol.* 2006;7:85-96.
- [39] Pessayre D, Fromenty B. NASH: a mitochondrial disease. *J Hepatol.* 2005;42:928-40.
- [40] Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion.* 2006;6:1-28.
- [41] Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. *World J Gastroenterol.* 2014;20:14205-18.
- [42] Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes.* 2009;16:141-9.
- [43] Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat Rev Cancer.* 2014;14:581-97.
- [44] Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. *Hepatol Res.* 2005;33:132-4.
- [45] Schattenberg JM, Singh R, Wang Y, Lefkowitz JH, Rigoli RM, Scherer PE, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. *Hepatology.* 2006;43:163-72.
- [46] Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. *Gastroenterology.* 2008;134:568-76.
- [47] Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science.* 2004;306:457-61.

- [48] Kapoor A, Sanyal AJ. Endoplasmic reticulum stress and the unfolded protein response. *Clin Liver Dis.* 2009;13:581-90.
- [49] Park SW, Zhou Y, Lee J, Lu A, Sun C, Chung J, et al. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. *Nat Med.* 2010;16:429-37.
- [50] Winnay JN, Boucher J, Mori MA, Ueki K, Kahn CR. A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. *Nat Med.* 2010;16:438-45.
- [51] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology.* 2010;52:1836-46.
- [52] Hotamisligil GS. Inflammation and metabolic disorders. *Nature.* 2006;444:860-7.
- [53] Wullaert A, van Loo G, Heynink K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. *Endocr Rev.* 2007;28:365-86.
- [54] Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med.* 2005;11:183-90.
- [55] Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. *Am J Gastroenterol.* 2004;99:1708-17.
- [56] Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. *Gut.* 2006;55:415-24.

- [57] Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology*. 2001;34:1158-63.
- [58] Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature*. 2004;431:461-6.
- [59] Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature*. 2012;481:278-86.
- [60] Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. *Gastroenterology*. 2010;139:323-34 e7.
- [61] Watanabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS, et al. Inflammasome-mediated regulation of hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol*. 2009;296:G1248-57.
- [62] Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. *Hepatology*. 2011;54:133-44.
- [63] Wree A, McGeough MD, Pena CA, Schlattjan M, Li H, Inzaugarat ME, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. *J Mol Med (Berl)*. 2014;92:1069-82.
- [64] Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. *Annu Rev Immunol*. 2010;28:321-42.



- [65] Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. *Hepatology*. 2010;51:511-22.
- [66] Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. *Hepatology*. 2010;52:1769-82.
- [67] Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. *Mediators Inflamm*. 2009;2009:831670.
- [68] Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. *J Lipid Res*. 2007;48:1905-14.
- [69] Makino T, Noguchi Y, Yoshikawa T, Doi C, Nomura K. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. *Br J Surg*. 1998;85:1658-62.
- [70] Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. *J Clin Endocrinol Metab*. 2001;86:1154-9.
- [71] du Plessis J, van Pelt J, Korf H, Mathieu C, van der Schueren B, Lannoo M, et al. Association of Adipose Tissue Inflammation With Histological Severity of Non-alcoholic Fatty Liver Disease. *Gastroenterology*. 2015.
- [72] Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. *Proc Natl Acad Sci U S A*. 2000;97:8536-41.

- [73] Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. *Scand J Gastroenterol*. 2008;43:1128-36.
- [74] Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. *Hepatology*. 2001;34:288-97.
- [75] Choi SS, Syn WK, Karaca GF, Omenetti A, Moylan CA, Witek RP, et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. *J Biol Chem*. 2010;285:36551-60.
- [76] Aleffi S, Navari N, Delogu W, Galastri S, Novo E, Rombouts K, et al. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol*. 2011;301:G210-9.
- [77] Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, et al. Kupffer cells mediate leptin-induced liver fibrosis. *Gastroenterology*. 2009;137:713-23.
- [78] Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. *Cell Metab*. 2012;16:44-54.
- [79] Yang YY, Tsai TH, Huang YT, Lee TY, Chan CC, Lee KC, et al. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. *Hepatology*. 2012;55:1540-50.
- [80] Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. *Am J Gastroenterol*. 2006;101:2629-40.

- [81] Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. *Gastroenterology*. 2006;131:934-45.
- [82] Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. *Nat Med*. 2011;17:55-63.
- [83] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol*. 2006;6:772-83.
- [84] Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. *Gastroenterology*. 2003;125:1796-807.
- [85] Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. *Hepatology*. 2008;47:677-85.
- [86] Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest*. 2003;112:91-100.
- [87] Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1 $\alpha$  and mitochondria by Ca<sup>2+</sup> and AMPK/SIRT1. *Nature*. 2010;464:1313-9.
- [88] Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. *Semin Liver Dis*. 2011;31:128-46.
- [89] Anstee QM, Day CP. The genetics of NAFLD. *Nat Rev Gastroenterol Hepatol*. 2013;10:645-55.

- [90] Mancina RM, Matikainen N, Maglio C, Soderlund S, Lundbom N, Hakkarainen A, et al. Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. *J Clin Endocrinol Metab*. 2015;100:E821-5.
- [91] Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Stahlman M, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. *J Hepatol*. 2012;57:1276-82.
- [92] Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. *Hepatology*. 2015;61:108-18.
- [93] Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology*. 2011;53:1883-94.
- [94] Palmer ND, Musani SK, Yerges-Armstrong LM, Feitosa MF, Bielak LF, Hernaez R, et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. *Hepatology*. 2013;58:966-75.
- [95] Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. *Sci Rep*. 2015;5:9284.
- [96] Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol*. 2014;61:75-81.

- [97] Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet.* 2014;46:352-6.
- [98] Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun.* 2014;5:4309.
- [99] Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology.* 2015;61:506-14.
- [100] Zeybel M, Mann DA, Mann J. Epigenetic modifications as new targets for liver disease therapies. *J Hepatol.* 2013;59:1349-53.
- [101] Podrini C, Borghesan M, Greco A, Pazienza V, Mazzocchi G, Vinciguerra M. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). *Curr Pharm Des.* 2013;19:2737-46.
- [102] Pogribny IP, Tryndyak VP, Bagnyukova TV, Melnyk S, Montgomery B, Ross SA, et al. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. *J Hepatol.* 2009;51:176-86.
- [103] Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet.* 2003;33 Suppl:245-54.
- [104] Wang LJ, Zhang HW, Zhou JY, Liu Y, Yang Y, Chen XL, et al. Betaine attenuates hepatic steatosis by reducing methylation of the MTP promoter and elevating genomic methylation in mice fed a high-fat diet. *J Nutr Biochem.* 2014;25:329-36.

- [105] Pooya S, Blaise S, Moreno Garcia M, Giudicelli J, Alberto JM, Gueant-Rodriguez RM, et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-1 $\alpha$  hypomethylation and decreased ER- $\alpha$ , ERR- $\alpha$ , and HNF-4 $\alpha$  in the rat liver. *J Hepatol*. 2012;57:344-51.
- [106] Caballero F, Fernandez A, Matias N, Martinez L, Fucho R, Elena M, et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. *J Biol Chem*. 2010;285:18528-36.
- [107] Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1 $^{+/-}$  mice: a role of lipid mobilization and inflammation. *Endocrinology*. 2010;151:2504-14.
- [108] Moschen AR, Wieser V, Gerner RR, Bichler A, Enrich B, Moser P, et al. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. *J Hepatol*. 2013;59:1315-22.
- [109] Dudley KJ, Sloboda DM, Connor KL, Beltrand J, Vickers MH. Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation. *PLoS One*. 2011;6:e21662.
- [110] Aagaard-Tillery KM, Grove K, Bishop J, Ke X, Fu Q, McKnight R, et al. Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. *J Mol Endocrinol*. 2008;41:91-102.
- [111] Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. *Cell Metab*. 2013;18:296-302.

- [112] Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. *World J Gastroenterol*. 2014;20:15079-86.
- [113] Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. *Hepatology*. 2008;48:1810-20.
- [114] Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. *World J Gastroenterol*. 2012;18:6546-51.
- [115] Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. *Nature*. 2005;438:685-9.
- [116] Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. *Hepatology*. 2014;59:471-82.
- [117] Kechagias S, Ernerosson A, Dahlqvist O, Lundberg P, Lindstrom T, Nystrom FH, et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. *Gut*. 2008;57:649-54.
- [118] Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. *J Hepatol*. 2008;48:983-92.
- [119] Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. *Nutrients*. 2014;6:5679-703.

[120] Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. *Hepatology*. 2009;50:1094-104.

[121] Song M, Schuschke DA, Zhou Z, Chen T, Pierce WM, Jr., Wang R, et al. High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. *J Hepatol*. 2012;56:433-40.

[122] Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology*. 2010;51:1961-71.

[123] Petta S, Marchesini G, Caracausi L, Macaluso FS, Camma C, Ciminnisi S, et al. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. *J Hepatol*. 2013;59:1169-76.

[124] Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. *Hepatology*. 2012;56:952-60.

[125] Ma J, Fox CS, Jacques PF, Speliotes EK, Hoffmann U, Smith CE, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. *J Hepatol*. 2015;63:462-9.

[126] Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. *Hepatology*. 2012;55:429-36.



- [127] Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. *Hepatology*. 2010;52:1652-61.
- [128] Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. *J Hepatol*. 2008;49:758-67.
- [129] Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol*. 2013;59:138-43.
- [130] Kanuri G, Landmann M, Priebs J, Spruss A, Loscher M, Ziegenhardt D, et al. Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. *Eur J Nutr*. 2015.
- [131] Duly AM, Alani B, Huang EY, Yee C, Haber PS, McLennan SV, et al. Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity. *Nutr Diabetes*. 2015;5:e154.
- [132] Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. *J Hepatol*. 2015;62:921-7.
- [133] Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. *Gut*. 2014;63:530-2.
- [134] Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature*. 2011;473:174-80.

- [135] Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444:1027-31.
- [136] Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? *Trends Microbiol*. 2004;12:562-8.
- [137] Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *J Hepatol*. 2007;47:571-9.
- [138] Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology*. 2009;49:1877-87.
- [139] Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut*. 2001;48:206-11.
- [140] Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev*. 2001;81:1031-64.
- [141] Zeisel SH, Wishnok JS, Blusztajn JK. Formation of methylamines from ingested choline and lecithin. *J Pharmacol Exp Ther*. 1983;225:320-4.
- [142] Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. *Gastroenterology*. 2011;140:976-86.

[143] Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. *Nature*. 2012;489:242-9.

[144] Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. *Gastroenterology*. 2000;119:1340-7.

[145] Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology*. 2013;57:601-9.

[146] Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature*. 2012;482:179-85.

[147] Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis*. 2009;13:511-31.

### **Captions**

Figure 1. Natural history of NAFLD.

Abbreviations: NAFLD, non-alcoholic fatty liver disease; CVD, cardiovascular disease; NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; (% prevalence/incidence); \*In 10 years from development of cirrhosis [147].

**The term NAFLD encompasses a wide spectrum of conditions, from simple accumulation of fat ('fatty liver' or steatosis) to steatohepatitis (NASH), fibrosis and cirrhosis with its clinical consequences. Despite the high prevalence of NAFLD in the general population, the vast majority of patients have simple steatosis, which is not associated with impaired survival. Only 5-10% of patients diagnosed with NAFLD will develop NASH and 30% of these will develop cirrhosis.**

Figure 2. Multiple hit hypothesis for the development of NAFLD

Abbreviations: FFAs, free fatty acids; DNL, de novo lipogenesis; VLDL, very low density lipoproteins; CH, cholesterol; TNF- $\alpha$ , tumor necrosis factor alpha; IL-6, interleukin 6; TG, triglycerides; ROS, reactive oxygen species; ER, endoplasmic reticulum; UPR, unfolded protein response; LPS, lipopolysaccharide; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.

Dietary and environmental factors, together with obesity, lead to raised serum levels of fatty acids (FFAs) and cholesterol (CH), development of insulin resistance, adipocyte proliferation and dysfunction and changes in the intestinal microbiome.

Insulin resistance acts on adipose tissue worsening adipocyte dysfunction, induces lipolysis and release of adipokines and proinflammatory cytokines such as TNF- $\alpha$  and IL-6, which also contribute to maintain the insulin resistance state. In the liver, insulin resistance amplifies DNL.

The increased hepatic FFAs flux which derives from the above processes and from an altered activity of the gut microbiome leads to two different situations: synthesis and accumulation of triglycerides (TG) and 'toxic' levels of fatty acids, free cholesterol and other lipid metabolites which cause mitochondrial dysfunction with oxidative stress and production of ROS and endoplasmic reticulum (ER) stress with activation of UPR, all leading to hepatic inflammation.

Also, small bowel permeability can be enhanced with consequent raised circulating levels of molecules which contribute to the activation of inflammasome and ER stress, such as LPS, and to the release of pro-inflammatory cytokines.

Genetic factors or epigenetic modifications affect hepatocyte fat content, enzymatic processes and liver inflammatory environment, thus influencing the risk of progression to inflammation and fibrosis (NASH) or persistence in a stable stage of disease (NAFLD).